Introduction: Recombinant bone morphogenetic proteins (rhBMPs) are approved for limited use as adjunctive orthopedic therapy. BMPs are not, however, recommended in the reconstruction of maxillofacial-skeletal defects caused by ablative cancer surgery, as their effects on residual carcinoma cells are unknown. Objective: The aim of this study was to determine the effects of BMP-2 and -7 on oral squamous carcinoma cell proliferation, and secretion of the proangiogenic factors IL-8 and VEGF. Methods: PCR was used to quantify transcripts of BMP-2, and –7, and BMP receptors Ia, Ib, II, and Act receptors I, IIa, and IIb in oral squamous carcinoma cell lines UMSCC-1, UMSCC-14 and UMSCC-74. Proliferation of the cell lines were evaluated at 24 to 96 hrs after incubation in varying concentrations of rhBMP-2 and -7 (0-500 ng/ml) or infection with an adenovirus expressing BMP-2 or -7 (AdBMP-2 and AdBMP-7, moi=0-1000). The supernatant of cells was evaluated via ELISA for expression of VEGF and IL-8. Results: BMP receptors Ia, Ib, and Act receptors I and IIa were expressed by all three cell lines. No significant increase in proliferation of any cell lines was observed with exposure to BMP-2 or -7 protein or when cells were transduced with AdBMP-2 or -7 gene (p<.05). There was no evidence of a significant increase in IL-8 or VEGF expression in any of the cell lines studied following exposure to BMP-2 or -7 protein or AdBMP-2 or -7 (p<.05). Conclusions: These results suggest that BMP proteins or BMP gene transduction does not increase the proliferation or the secretion of proangiogenic factors in oral squamous cell carcinoma cell lines in vitro.

Back to the AADR/Pfizer Hatton Awards Program
Back to the IADR/AADR/CADR 85th General Session and Exhibition (March 21-24, 2007)

Top Level Search